ECSP066735A - Formas polimórficas de un agonista de gabaa - Google Patents

Formas polimórficas de un agonista de gabaa

Info

Publication number
ECSP066735A
ECSP066735A EC2006006735A ECSP066735A ECSP066735A EC SP066735 A ECSP066735 A EC SP066735A EC 2006006735 A EC2006006735 A EC 2006006735A EC SP066735 A ECSP066735 A EC SP066735A EC SP066735 A ECSP066735 A EC SP066735A
Authority
EC
Ecuador
Prior art keywords
polymodic
forms
gabaa agonist
gabaa
agonist
Prior art date
Application number
EC2006006735A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Brett Cooper
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP066735A publication Critical patent/ECSP066735A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2006006735A 2004-01-30 2006-07-28 Formas polimórficas de un agonista de gabaa ECSP066735A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
ECSP066735A true ECSP066735A (es) 2006-10-31

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006735A ECSP066735A (es) 2004-01-30 2006-07-28 Formas polimórficas de un agonista de gabaa

Country Status (34)

Country Link
US (2) US7262300B2 (enExample)
EP (2) EP2042505A1 (enExample)
JP (1) JP4917440B2 (enExample)
KR (1) KR101210361B1 (enExample)
CN (1) CN1914212B (enExample)
AR (1) AR047511A1 (enExample)
AT (1) ATE414088T1 (enExample)
AU (1) AU2005209473B2 (enExample)
BR (1) BRPI0506858A (enExample)
CA (1) CA2554536C (enExample)
CO (1) CO5700743A2 (enExample)
CY (1) CY1108647T1 (enExample)
DE (1) DE602005010975D1 (enExample)
DK (1) DK1713813T3 (enExample)
DO (1) DOP2005000013A (enExample)
EA (1) EA009413B1 (enExample)
EC (1) ECSP066735A (enExample)
ES (1) ES2314613T3 (enExample)
GB (2) GB0402118D0 (enExample)
HR (1) HRP20080614T3 (enExample)
IL (1) IL176863A0 (enExample)
MA (1) MA28364A1 (enExample)
MX (1) MXPA06008595A (enExample)
MY (1) MY139525A (enExample)
NO (1) NO20063843L (enExample)
NZ (1) NZ548191A (enExample)
PE (1) PE20050769A1 (enExample)
PL (1) PL1713813T3 (enExample)
PT (1) PT1713813E (enExample)
SI (1) SI1713813T1 (enExample)
TW (1) TWI345972B (enExample)
UA (1) UA87487C2 (enExample)
WO (1) WO2005073237A2 (enExample)
ZA (1) ZA200605307B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
BRPI0520588B8 (pt) 2005-09-28 2021-05-25 Auris Medical Ag uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
MXPA03010610A (es) 2001-05-18 2004-04-02 Lonza Ag Metodo para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
CZ20033269A3 (en) 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP2145620A3 (en) 2003-06-25 2010-03-17 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2572302A1 (en) 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL

Also Published As

Publication number Publication date
DOP2005000013A (es) 2005-08-15
CN1914212B (zh) 2010-10-06
HK1096547A1 (en) 2007-06-01
NZ548191A (en) 2010-04-30
PE20050769A1 (es) 2005-10-04
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
SI1713813T1 (sl) 2009-02-28
PL1713813T3 (pl) 2009-04-30
KR101210361B1 (ko) 2012-12-10
MY139525A (en) 2009-10-30
TWI345972B (en) 2011-08-01
CN1914212A (zh) 2007-02-14
CY1108647T1 (el) 2014-04-09
GB0501847D0 (en) 2005-03-09
US7262300B2 (en) 2007-08-28
EA200601404A1 (ru) 2006-12-29
ZA200605307B (en) 2007-11-28
CA2554536C (en) 2012-09-18
JP4917440B2 (ja) 2012-04-18
PT1713813E (pt) 2008-12-26
WO2005073237A3 (en) 2005-10-20
BRPI0506858A (pt) 2007-05-29
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
EP2042505A1 (en) 2009-04-01
IL176863A0 (en) 2006-10-31
CO5700743A2 (es) 2006-11-30
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
AU2005209473B2 (en) 2010-03-04
MA28364A1 (fr) 2006-12-01
NO20063843L (no) 2006-08-29
US20050171142A1 (en) 2005-08-04
EP1713813A2 (en) 2006-10-25
JP2007519697A (ja) 2007-07-19
TW200534856A (en) 2005-11-01
US8236958B2 (en) 2012-08-07
WO2005073237A2 (en) 2005-08-11
DE602005010975D1 (de) 2008-12-24
EP1713813B1 (en) 2008-11-12
AR047511A1 (es) 2006-01-25
GB2410434A (en) 2005-08-03
ES2314613T3 (es) 2009-03-16
ATE414088T1 (de) 2008-11-15
GB0402118D0 (en) 2004-03-03
CA2554536A1 (en) 2005-08-11
DK1713813T3 (da) 2009-02-16
AU2005209473A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ECSP066735A (es) Formas polimórficas de un agonista de gabaa
ES2458216T8 (es) Nuevos ARNip y métodos de uso de los mismos
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
ECSP088831A (es) Anticuerpos anti-tat226 e inmunoconjugados
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
BRPI0720993A2 (pt) métodos de uso para análogos de ciclopamina
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
SV2011003832A (es) Derivados de ciclohexil-amida y su uso como antagonistas de los receptores de crf-1
CR10734A (es) Anticuerpos e inmunoconjugados y sus usos
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
ECSP088924A (es) Anticuerpos e inmunoconjugados y sus usos
MX386852B (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
DK1888582T3 (da) Imidazo- og triazolopyridiner som hæmmere af 11-beta-hydroxysteroid dehydrigenase
DK1756679T3 (da) Fremgangsmåde til tidsstyring af et objekt
DK1636190T3 (da) Stabilt krystal af 4-oxoquinolinforbindelse
DK1928872T3 (da) Hidtil ukendte sulfonylpyrroler som inhibitorer af hdac
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
ES2530578T3 (es) Cristales y cristales reticulados de Proteína A y métodos de uso de los mismos
DK1917227T3 (da) Krystalformer af astaxanthin
ES1065291Y (es) Dispositivo para la mejora del rendimiento de los paneles solares
DK2167124T3 (da) Anvendelse af monomycolylglycerol (MMG) som adjuvans
UY30801A1 (es) Compuestos calciliticos
DK3805671T3 (da) Absorption af brændbart kølemiddel